Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 2005;97:1124-1131
Published online before print November 3, 2005, doi: 10.1161/01.RES.0000194323.77203.fe
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
97/11/1124    most recent
01.RES.0000194323.77203.fev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mineo, C.
Right arrow Articles by Shaul, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mineo, C.
Right arrow Articles by Shaul, P. W.
Related Collections
Right arrow Risk Factors
Right arrow Cell signalling/signal transduction
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2005;97:1124.)
© 2005 American Heart Association, Inc.

Molecular Medicine

Fc{gamma}RIIB Mediates C-Reactive Protein Inhibition of Endothelial NO Synthase

Chieko Mineo*, Andrew K. Gormley*, Ivan S. Yuhanna, Sherri Osborne-Lawrence, Linda L. Gibson, Lisa Hahner, Ralph V. Shohet, Steven Black, Jane E. Salmon, David Samols, David R. Karp, Gail D. Thomas, Philip W. Shaul

From the Departments of Pediatrics (C.M., A.K.G., I.S.Y., S.O.-L., L.L.G., L.H., P.W.S.) and Internal Medicine (R.V.S., D.R.K., G.D.T.), University of Texas Southwestern Medical Center, Dallas; Department of Medicine (J.E.S.), Cornell University Weill Medical College, New York, NY; and Department of Biochemistry (S.B., D.S.), Case Western Reserve University School of Medicine, Cleveland, Ohio.

Correspondence to Philip W. Shaul, Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX. E-mail philip.shaul{at}utsouthwestern.edu


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
C-reactive protein (CRP) is an acute-phase reactant that is positively correlated with cardiovascular disease risk and endothelial dysfunction. Whether CRP has direct actions on endothelium and the mechanisms underlying such actions are unknown. Here we show in cultured endothelium that CRP prevents endothelial NO synthase (eNOS) activation by diverse agonists, resulting in the promotion of monocyte adhesion. CRP antagonism of eNOS occurs nongenomically and is attributable to blunted eNOS phosphorylation at Ser1179. Okadaic acid or knockdown of PP2A by short-interference RNA reverses CRP antagonism of eNOS, indicating a key role for the phosphatase. Aggregated IgG, the known ligand for Fc{gamma} receptors, causes parallel okadaic acid–sensitive loss of eNOS function, Fc{gamma}RIIB expression is demonstrable in endothelium, and heterologous expression studies reveal that CRP antagonism of eNOS requires Fc{gamma}RIIB. In Fc{gamma}RIIB+/+ mice, CRP blunts acetylcholine-induced increases in carotid artery vascular conductance; in contrast, CRP enhances acetylcholine responses in Fc{gamma}RIIB–/– mice. Thus Fc{gamma}RIIB mediates CRP inhibition of eNOS via PP2A, providing a mechanistic link between CRP and endothelial dysfunction.


Key Words: C-reactive protein • endothelial NO synthase • Fc{gamma} receptor • PP2A


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
C-reactive protein (CRP) is an acute-phase reactant and a member of the pentraxin family of proteins. Its hepatic synthesis is stimulated by interleukin-6 to yield levels that can rise 500-fold within 24 to 48 hours of the initiation of an inflammatory process. CRP serves as an opsonin and activates complement by binding to C1q.1–4

In addition to participating in immune response, CRP has received considerable attention as a risk factor for cardiovascular disease. Although the relative predictive value of CRP versus other risk factors has been variable, the finding that CRP levels correlate with cardiovascular disease has been remarkably consistent across populations.5–9 CRP is also a risk factor for the progression of subclinical vascular disease and for hypertension.10,11 Furthermore, a primary effect of CRP on endothelium is plausible because elevated levels are associated with endothelial dysfunction, as evidenced by blunted forearm vascular responses to acetylcholine (Ach), which activates endothelial NO synthase (eNOS) to generate NO on L-arginine conversion to L-citrulline.12 Potentially consistent with these clinical observations, CRP transgenic mice have exaggerated thrombosis,13 and CRP blunts eNOS expression and function in cultured endothelial cells.14,15 However, it has yet to be determined whether CRP has direct effects on vascular endothelium in vivo, and the basis for such effects is unknown.

In the present study, we investigated the mechanisms underlying CRP actions on endothelium by testing the hypothesis that CRP attenuates eNOS activation in cultured endothelial cells. The resulting effect on monocyte adhesion was also determined. Because eNOS activation entails phosphatidylinositol 3-kinase–mediated increases in Ser1179 phosphorylation, which are counter-regulated by the phosphatase PP2A,16–18 alterations in Ser1179 phosphorylation and the potential involvement of PP2A were investigated. To further identify the basis for this process, additional experiments tested the role of Fc{gamma} receptors for IgG, which display high affinity for CRP and modulate CRP actions in immune response cells.19–23 Moreover, studies of CRP-induced changes in endothelial function were performed in mice to delineate whether these mechanisms are operative in vivo.


*    Materials and Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Materials and Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Cell Culture and Transfection
Primary bovine aortic endothelial cells (BAEC) and human aortic endothelial cells (HAEC) (Cambrex Corp) were used within 7 passages. MFLM-4 were provided by Dr Ann Akeson (Children’s Hospital Medical Center, Cincinnati, Ohio). To study the role of Fc{gamma}RIIB, Fc{gamma}RII-negative COS-7 cells were transfected with human Fc{gamma}RIIB1 cDNA (a gift from Dr Catherine Sautes-Fridman, Paris, France),24 selected with Zeocin (Invitrogen), and cloned by limiting dilution. Fc{gamma}RIIB expression was tested by fluorescence-activated cell sorting (FACS) with the monoclonal antibody AT10 (provided by Dr P.M. Morganelli, White River Junction, Vermont). Zeocin-resistant cells not expressing detectable Fc receptor (FcR) served as controls.

eNOS Activation Assays
eNOS activation was assessed in whole cells by measuring [3H]L-arginine conversion to [3H]L-citrulline.25 Cell treatments included human recombinant CRP (Calbiochem), ascites-derived human CRP, purified and characterized as previously described,26 or human recombinant serum amyloid P component (SAP) (Calbiochem) added during a 15-minute preincubation and the 15-minute incubation for eNOS activation. For additional details, see the online data supplement available at http://circres.ahajournals.org. Control cells were exposed to CRP or SAP heated at 100°C for 60 minutes. Stimulated activity is expressed as percentage of basal activity, and results were confirmed in 3 experiments. eNOS activation was also evaluated ex vivo in isolated carotid arteries from 10- to 12-week-old male C57BL/6 mice by measuring cGMP accumulation during 2-minute incubations.27 The care and use of all study animals was approved by the International Animal Care and Use Committee at the University of Texas Southwestern Medical Center.

Monocyte Adhesion Assays
The adhesion of U937 cells to monolayers of BAEC was evaluated as previously described.28 Following U937 and endothelial cell coincubation and washing, cells were fixed and the number of adherent cells was counted. See the online data supplement for additional details.

Short-Interference RNA Preparation and Transfection
Double-stranded RNA with sequence 5'-CCAAGCUGCAAUCAUGGAA-3' was designed to target the open reading frame of the bovine PP2A catalytic subunit C{alpha}29 (GenBank accession no. M16968). Scrambled sequence served as control. BAEC were transfected with 80 nmol/L RNA as described previously,30 and PP2A expression and eNOS activation were assessed 48 hours posttransfection.

Immunoblot Analyses
Immunoblots were performed to assess eNOS phosphorylation using anti–phospho-Ser1179 eNOS antibody (Cell Signaling Technology) and total eNOS abundance using eNOS monoclonal antibody (BD Biosciences Pharmingen).31 BAEC were starved overnight in the absence of serum or phenol red in DMEM before eNOS agonist treatment. Results shown were confirmed in 3 independent experiments.

RT-PCR for Fc{gamma}RIIA/B in Endothelium
Fc{gamma}RIIA/B expression was evaluated in HAEC by RT-PCR using Raji cells as positive controls. To assess and quantitate receptor expression in native endothelium, real-time RT-PCR studies were performed using RNA from endothelial cells isolated from the aorta, carotid artery, and heart of Tie2–green fluorescent protein (GFP) transgenic mice by FACS analysis.32 See the online data supplement for additional details.

Carotid Artery Vascular Conductance in Mice
To determine whether CRP alters signaling to eNOS in vivo, Ach-induced changes in carotid artery vascular conductance were measured shortly before and after IP vehicle or CRP administration in mice.33 Studies were performed at 10 to 12 weeks of age in male C57BL/6 mice or in male Fc{gamma}RIIB+/+ versus Fc{gamma}RIIB–/– B6:129S mice (Jackson Laboratory).34 The dose of CRP used (250 µg IP) yielded serum levels of 38±4 µg/mL (n=6). See the online data supplement for additional details.

Statistical Analysis
Student t tests or ANOVA with Neuman–Keuls post hoc testing were used to assess differences between 2 groups or among more than 2 groups, respectively, and significance was set at P<0.05.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 *Results
down arrowDiscussion
 down arrowReferences
 
CRP Antagonism of eNOS Activation
To determine whether CRP alters eNOS activation, BAEC or HAEC were preincubated with heat-treated (control) or nontreated recombinant human CRP (5 µg/mL), and eNOS stimulation was evaluated (Figure 1, left and right for BAEC and HAEC, respectively). Vascular endothelial growth factor (VEGF) stimulation of eNOS in either BAEC or HAEC was attenuated by CRP (Figure 1A). Similarly, CRP blunted eNOS activation by high-density lipoprotein (HDL) (Figure 1B) and by insulin (Figure 1C). Thus, CRP attenuates eNOS activation mediated by diverse agonists, intact CRP protein is required, and the process occurs in bovine and human endothelium.



View larger version (27K):
[in this window]
[in a new window]
  		Figure 1. CRP inhibits eNOS activation by diverse agonists. BAEC were exposed to heat-treated (control) or active CRP (5 µg/mL), and eNOS stimulation by 2.4 pmol/L (100 ng/mL) VEGF was assessed (A, left). The impact of CRP on eNOS activation by VEGF was also evaluated in HAEC (A, right). Parallel studies were performed examining eNOS stimulation by 10 µg/mL HDL in BAEC or HAEC (B) and activation by 500 nmol/L insulin in BAEC or HAEC (C). Values are mean±SEM (n=4 to 6). *P<0.05 vs basal, {dagger}P<0.05 vs control.

Lipopolysaccharide (LPS) was not responsible for the observed effects on eNOS. Whereas CRP (5 µg/mL) potently attenuated VEGF-stimulated eNOS activity, LPS (5 µg/mL) had no effect (Figure 2A). In addition, human recombinant CRP and ascites-derived CRP26 caused comparable inhibition of eNOS activation (Figure 2B). SAP, the related pentraxin that is 60% homologous to CRP,35 also blocked eNOS activation (Figure 2C), and dose-response studies showed CRP effects at 5 µg/mL and SAP effects at 2 µg/mL (Figure 2D). These findings indicate that levels of CRP that have been associated with the risk of cardiovascular disease (3 to 10 µg/mL)1 are operative and that the capacity to block eNOS activation is shared by CRP and SAP.



View larger version (28K):
[in this window]
[in a new window]
  		Figure 2. CRP inhibition of eNOS activation is independent of LPS and mimicked by SAP. A, BAEC were exposed to buffer alone (control) or buffer plus CRP or LPS (5 µg/mL), and activation by 2.4 pmol/L (100 ng/mL) VEGF was assessed. B, Actions of 5 µg/mL heat-treated CRP (control) vs active recombinant human CRP (rCRP) (left) and ascites-derived human CRP (aCRP) (right) were compared. C, Effects of heat-treated (control) vs active SAP (5 µg/mL) on eNOS activation by VEGF were evaluated. D, Dose responses to CRP and SAP were compared and expressed relative to VEGF-stimulated NOS activity in the absence of pentraxin (control). Values are mean±SEM (n=4 to 6). For A, B, and C, *P<0.05 vs basal, {dagger}P<0.05 vs control; for D, *P<0.05 vs control.

To determine whether CRP actions on eNOS alter endothelial cell function, the impact on monocyte adhesion was evaluated. LPS caused a marked increase in monocyte adhesion compared with control conditions (Figure 3A and 3B, respectively); this was reversed by the eNOS agonist insulin (Figure 3C), and the effect of insulin was confirmed to be NO dependent using NG-nitro-L-arginine methyl ester (L-NAME) (Figure 3D). CRP (3 µg/mL) prevented the lessening of adhesion with insulin (Figure 3E), and this was not related to a change in eNOS expression (data not shown). The impact of CRP on adhesion was fully reversed by S-nitroso-N-acetyl-D, L-penicillamine (Figure 3F). Thus, CRP-induced declines in NO production promote monocyte adhesion to endothelium.



View larger version (82K):
[in this window]
[in a new window]
  		Figure 3. CRP antagonism of eNOS promotes monocyte adhesion. Monocyte adhesion to BAEC was evaluated with the following: LPS treatment (100 ng/mL) (A); control treatment (B); LPS+insulin (Ins.) (500 nmol/L) (C); LPS+insulin+L-NAME (2 mmol/L) (D); LPS+insulin+CRP (3 µg/mL) (E); and LPS+insulin+CRP+S-nitroso-N-acetyl-D, L-penicillamine (20 µmol/L) (F). Images are representative optical fields. Values are mean±SEM for cells per x20 field (n=4 to 5). *P<0.05 vs control, {dagger}P<0.05 vs LPS alone.

eNOS Phosphorylation and Involvement of PP2A
To define the mechanisms underlying CRP antagonism of eNOS, we first determined whether changes in gene transcription are involved. CRP caused comparable blockade of VEGF activation of eNOS in control and actinomycin D–treated cells (Figure 4A), indicating that CRP action is transcription independent. Because eNOS stimulation entails phosphatidylinositol 3-kinase–mediated increases in Ser1179 phosphorylation,17 changes in phosphorylation of the enzyme were investigated. Using HDL as agonist, an increase in phosphorylated eNOS occurred in control cells but not in CRP-treated cells (Figure 4B, top). Under these conditions, CRP exposure did not alter total eNOS abundance. The increase in eNOS phosphorylation by insulin was similarly blunted by CRP (Figure 4B, bottom), and comparable findings were obtained with estradiol-17ß (10 nmol/L) (data not shown) or VEGF as agonist (Figure 4C). Because PP2A controls eNOS phosphorylation at Ser1179,16,18 the effect of the selective PP2A inhibitor okadaic acid (100 nmol/L) was investigated. In contrast to the diminution in eNOS phosphorylation observed with CRP alone, okadaic acid rescued Ser1179 phosphorylation in the presence of CRP (Figure 4C). In parallel, VEGF-stimulated eNOS activity was rescued by okadaic acid (Figure 4D). To confirm involvement of PP2A, short-interference RNA (siRNA) was used to diminish expression of the phosphatase in BAEC. With a 53% decline in PP2A protein expression (Figure 4E, inset), there was a parallel 48% rescue of eNOS activation by VEGF in the presence of CRP (Figure 4E). We also determined whether CRP blunts eNOS stimulation by bradykinin, which entails intracellular calcium elevation and eNOS phosphorylation.36 CRP inhibited bradykinin-induced eNOS phosphorylation and activation in an okadaic acid–sensitive manner (Figure 4F and 4G, respectively). These cumulative findings indicate that the negative modulation of eNOS by CRP is mediated by PP2A-induced changes in phosphorylation.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 4. CRP inhibits eNOS activation in a transcription-independent manner via alterations in eNOS phosphorylation mediated by PP2A. A, BAEC were preincubated in the absence (control) or presence of actinomycin D (20 µmol/L, 25 µg/mL) before preincubation with vehicle (control) or CRP (5 µg/mL), and eNOS activation by 2.4 pmol/L (100 ng/mL) VEGF was assessed in the continued absence or presence of actinomycin and/or CRP. B, BAEC were preincubated in the absence or presence of 5 µg/mL CRP and treated with 10 µg/mL HDL (top) or 500 nmol/L insulin (bottom) with or without CRP present, and lysates were analyzed by immunoblot analysis using polyclonal anti–phospho-Ser1179 eNOS (peNOS) or monoclonal eNOS antibodies. C, BAEC were preincubated in the absence or presence of CRP, okadaic acid (OK) (100 nmol/L), or CRP plus OK and treated with VEGF, and lysates were analyzed for phospho-eNOS (peNOS) or total eNOS. D, BAEC were preincubated in the absence or presence of OK, CRP, or OK and CRP, and eNOS activation by VEGF was assessed in the continued absence or presence of OK and/or CRP. E, BAEC were transfected with control or PP2A siRNA for 48 hours, and eNOS activation by VEGF was assessed with or without CRP. With PP2A siRNA, expression of the phosphatase declined by 52.9%±7.3 (values are mean±SEM; n=6), whereas eNOS expression was unchanged (inset). F, BAEC were preincubated in the absence or presence of CRP, OK, or CRP plus OK and treated with bradykinin (BK) (10 µmol/L, 5 minutes), and lysates were analyzed for phospho-eNOS or total eNOS. G, BAEC were preincubated in the absence or presence of OK, CRP, or OK and CRP, and eNOS activation by bradykinin was assessed in the continued absence or presence of OK and/or CRP. In A, D, E, and G, values are mean±SEM (n=4 to 6). *P<0.05 vs basal, {dagger}P<0.05 vs no CRP. Findings shown for immunoblots are representative of 3 or more independent experiments.

CRP Action In Vivo
In preparation for in vivo studies of CRP action in mice, the effect of CRP on Ach-mediated eNOS activation was evaluated in MFLM-4 mouse endothelial cells. eNOS stimulation by Ach was absent in CRP-treated cells (Figure 5A). CRP also caused blunted cGMP accumulation with Ach in isolated mouse carotid arteries (Figure 5B). In contrast, cGMP accumulation with the NO donor sodium nitroprusside was not altered by CRP (data not shown). Thus, CRP antagonizes Ach activation of eNOS ex vivo in mouse endothelium. Paralleling the findings with other agonists, CRP inhibited Ach-induced eNOS phosphorylation and activation in an okadaic acid–sensitive manner (Figure 5C and 5D, respectively). Thus, CRP blockade of signaling by Ach typifies the impact of CRP on multiple mediators of endothelial function.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 5. CRP inhibits Ach stimulation of eNOS in vitro and in vivo. A, Cultured MFLM-4 were preincubated in the presence or absence of CRP (5 µg/mL), and activation by 10 µmol/L Ach was assessed in the continued presence of vehicle or CRP. Values are mean±SEM (n=4 to 6). *P<0.05 vs basal, {dagger}P<0.05 vs no CRP. B, Carotid arteries isolated from 10- to 12-week-old male C57BL/6 mice were preincubated in media containing control buffer or buffer with CRP and incubated with Ach in the continued presence of vehicle or CRP, and cGMP accumulation was measured and expressed as picomoles per artery segment. Values are mean±SEM (n=12). *P<0.05 vs control. C, BAEC were preincubated in the absence or presence of CRP or CRP plus okadaic acid (OK) (100 nmol/L) and treated with Ach, and cell lysates underwent immunoblot analyses using polyclonal anti–phospho-Ser1179 eNOS (peNOS) or monoclonal eNOS antibodies. Findings shown are representative of 3 independent experiments. D, BAEC were preincubated in the absence or presence of OK, CRP, or OK plus CRP, and eNOS activation by Ach was assessed in the continued absence or presence of OK and/or CRP. Values are mean±SEM (n=4 to 6). *P<0.05 vs basal, {dagger}P<0.05 vs no CRP. E, C57BL/6 mice were instrumented, and changes in carotid artery conductance were measured in response to IP vehicle (control) or CRP administration. Dose responses to Ach were determined sequentially at baseline ({bullet}), 60 minutes after vehicle or CRP was injected IP ({circ}), and 10 minutes after the administration of L-NAME ({blacktriangledown}). Values are mean±SEM (n=5 to 6). *P<0.05 vs baseline.

To determine whether CRP attenuates eNOS activation in vivo, Ach-induced changes in carotid artery vascular conductance were measured in mice.33 Whereas the control vehicle had no effect (Figure 5E, left), following CRP administration the Ach response was blunted by 50% (Figure 5E, right). Thus, CRP actions on eNOS observed in cultured endothelium also occur in endothelium in vivo.

Role of FcRs
If the actions of CRP on eNOS require FcRs, which display high affinity for CRP and mediate its effects in immune response cells,1,19–23 FcR crosslinking should yield the same phenotype as CRP. Aggregated IgG (aIgG) caused a concentration-dependent diminution in eNOS activation by VEGF (Figure 6A). In addition, aIgG blunted Ser1179 phosphorylation and eNOS activation in response to VEGF in an okadaic acid–sensitive manner (Figure 6B and 6C). These findings indicate that FcRs modify eNOS function via the activation of PP2A.



View larger version (27K):
[in this window]
[in a new window]
  		Figure 6. IgG activation of FcR inhibits eNOS phosphorylation and activation via PP2A, and Fc{gamma}RIIB is expressed in endothelium. A, BAEC were preincubated in the absence or presence of aIgG, and activation by 100 ng/mL VEGF was assessed. Values are mean±SEM (n=4 to 6). *P<0.05 vs control, {dagger}P<0.05 vs no aIgG. B, BAEC were preincubated in the absence or presence of 10 µg/mL aIgG or aIgG plus okadaic acid (OK) (100 nmol/L) for 15 minutes, treated with VEGF with or without aIgG+OK present, and cell lysates were analyzed for phospho-eNOS (peNOS) or total eNOS. Findings shown are representative of 3 independent experiments. C, BAEC were preincubated in the absence or presence of OK, aIgG, or OK+aIgG, and eNOS activation by VEGF was assessed in the continued absence or presence of OK and/or aIgG. Values are mean±SEM (n=4 to 6). *P<0.05 vs basal, {dagger}P<0.05 vs no aIgG. D, RT-PCR was performed for Fc{gamma}RIIA and Fc{gamma}RIIB in the presence (+) or absence (–) of reverse-transcribed enzyme using RNA from Raji cells (positive control) or HAEC. E, Endothelial cells were purified from aorta, carotid artery, and heart of Tie2-GFP transgenic mice by FACS analysis for GFP. RNA was isolated and amplified, and quantitative real-time PCR was performed for eNOS (top) or Fc{gamma}RIIB (bottom). Expression of eNOS and Fc{gamma}RIIB were normalized to the housekeeping gene ß2-myoglobin.

We then determined whether Fc{gamma}RIIs, the principal high-affinity receptors for CRP, are expressed in endothelium. In humans, Fc{gamma}RIIA is an activation receptor, and Fc{gamma}RIIB is an inhibitory receptor, and only Fc{gamma}RIIB has been identified in mice.37 In studies of HAEC, RT-PCR demonstrated mRNA expression for Fc{gamma}RIIB but not Fc{gamma}RIIA (Figure 6D). To determine whether Fc{gamma}RIIB is expressed in endothelium in vivo, endothelial cells were purified by FACS analysis from the aorta, carotid artery, and heart of Tie2-GFP transgenic mice.32 Following RNA isolation and amplification, quantitative real-time RT-PCR showed that the abundance of mRNA for eNOS, the target of interest for CRP action, was greater in endothelium from aorta and carotid artery compared with cardiac endothelium (Figure 6E, top). Fc{gamma}RIIB mRNA was detected in greater abundance in aortic and cardiac endothelium compared with carotid artery endothelium (Figure 6E, bottom). Thus, Fc{gamma}RIIB is expressed in human endothelial cells and in mouse endothelium, and the level of expression varies between blood vessel types.

The causal role of Fc{gamma}RIIB in CRP antagonism of eNOS was then tested in COS-7 cells expressing eNOS and scavenger receptor B type I (SR-BI) to enable eNOS activation by HDL. In control cells not expressing Fc{gamma}RIIB, CRP did not antagonize eNOS activation (Figure 7A, left). In contrast, in cells expressing Fc{gamma}RIIB, CRP blunted eNOS activation (Figure 7A, right), indicating that the action of CRP requires Fc{gamma}RIIB. CRP binding specifically to Fc{gamma}RIIB in this system was confirmed by FACS analysis (data not shown). The requirement for Fc{gamma}RIIB was also tested in vivo in comparisons of Ach-mediated increases in carotid vascular conductance in Fc{gamma}RIIB+/+ and Fc{gamma}RIIB–/– mice. Control vehicle did not alter Ach responses in either Fc{gamma}RIIB+/+ or Fc{gamma}RIIB–/– mice (Figure 7B), and Ach-induced increases in conductance were attenuated by CRP in Fc{gamma}RIIB+/+ mice (Figure 7C, left). In sharp contrast, CRP did not blunt Ach responses in Fc{gamma}RIIB–/–, and instead Ach-induced increases in conductance were enhanced by CRP (Figure 7C, right). These in vivo findings confirm that Fc{gamma}RIIB is required for CRP inhibition of eNOS. Interestingly, because there was actual enhancement of the Ach vasodilatory response by CRP in Fc{gamma}RIIB–/– mice, other mechanisms of CRP action may have been unmasked in the absence of Fc{gamma}RIIB. We postulate that the latter processes may involve stimulatory FcRs such as Fc{gamma}RIII, which cause increases in intracellular calcium on their activation and thereby would potentially enhance eNOS activity.37



View larger version (33K):
[in this window]
[in a new window]
  		Figure 7. CRP inhibition of eNOS activation is mediated by Fc{gamma}RIIB. A, COS-7 cells expressing eNOS and SR-BI (control) (left) or eNOS, SR-BI, and Fc{gamma}RIIB (right) were preincubated with buffer alone or buffer plus 5 µg/mL CRP, and eNOS activation by 10 µg/mL HDL was assessed in the continued absence or presence of CRP. Values are mean±SEM (n=4 to 6). *P<0.05 vs basal, {dagger}P<0.05 vs no CRP. Fc{gamma}RIIB+/+ or Fc{gamma}RIIB–/– mice were instrumented, and changes in carotid artery conductance were measured in response to IP vehicle (control) (B) or CRP administration (C). Dose responses to Ach were determined sequentially at baseline ({bullet}), 60 minutes after vehicle or CRP was injected IP ({circ}), and 10 minutes after the administration of L-NAME ({blacktriangledown}). Values are mean±SEM (n=3 for control, n=7 for CRP). *P<0.05 vs baseline.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 *Discussion
down arrowReferences
 
CRP levels are strongly correlated with increased risk for cardiovascular disease and with endothelial dysfunction related to decreased NO bioavailability.5–12 However, the basis for potential effects of CRP on the endothelium has been unclear. Here we show that CRP causes potent antagonism of eNOS activation by diverse agonists resulting from changes in eNOS phosphorylation mediated by PP2A. Importantly, eNOS antagonism occurs at levels of CRP that have been associated with the risk of cardiovascular disease.1 When these processes are considered along with the previously known action of CRP to attenuate eNOS expression following prolonged exposure (24 hours),14,15 it is apparent that CRP decreases NO bioavailability by multiple mechanisms.

To link the effect of CRP on eNOS activation to a change in endothelial cell function, we show that CRP-induced declines in NO production underlie the promotion of monocyte adhesion by CRP in vitro. We also demonstrate in a mouse model that CRP antagonism of eNOS is operative in vivo. Such findings provide an explanation for the more than 50% decline in endothelium-dependent vasodilation that was recently observed following CRP infusion in hypercholesterolemic patients (E.S.G. Stroes, personal communication, 2005). Because there are multiple lines of evidence indicating that a loss in endothelial NO production plays a critical role in the pathogenesis of cardiovascular disease,38 we further propose that the resulting diminution in NO production may underlie the increased long-term cardiovascular risk associated with higher CRP levels in the absence of acute inflammation,8,39 as well as the poorer prognosis associated with even greater elevations in CRP during acute events.40 Whereas enhanced thrombosis has been effectively demonstrated in CRP transgenic mice,13 it is less clear from mouse models whether CRP accelerates atherogenesis.41–43 Considering the complexity and diversity of cardiovascular diseases and their etiologies, further studies of the direct impact of eNOS-related CRP actions on vascular health and disease in animal models are now warranted.

In addition to the observed actions of CRP on eNOS, we found that the related pentraxin SAP had comparable effect at physiologic levels. SAP is a major acute-phase reactant in the mouse and a constitutive protein in the blood of humans, with basal concentrations of 2 to 10 and 40 µg/mL, respectively.44,45 To date, SAP has not been associated with defects in vascular function. Although saturable binding of SAP to the IgG receptor subclass Fc{gamma}, in particular Fc{gamma}RI, Fc{gamma}RIIa, and Fc{gamma}RIIIb, has been described in transfected COS cells,3 SAP may not be accessible to the endothelium in vivo because of association with various proteins in the plasma or vasculature.46–48 More studies will be required to elucidate the role of SAP in vascular biology.

The known actions of CRP in immune-response cells are mediated by Fc{gamma} receptors, with Fc{gamma}RII acting as the principal high-affinity receptor.19–23 We demonstrate that human endothelial cells in culture and mouse endothelial cells in their native context express mRNA for Fc{gamma}RIIB. Attempts to detect Fc{gamma}RIIB protein in endothelium have been hindered by the lack of specificity of available antibodies and the low level of receptor abundance under quiescent conditions.49 However, using both gain-of-function and loss-of-function strategies in vitro and in vivo, we demonstrate that Fc{gamma}RIIB underlies the actions of CRP on vascular endothelium. Our studies are also the first to mechanistically link Fc{gamma}RIIB to PP2A in any paradigm, and the basis for the coupling of Fc{gamma}RIIB with PP2A warrants further investigation. Just as importantly, we show that the classical ligand for Fc{gamma} receptors, aIgG, has identical action to CRP in endothelium. It is well established that patients with rheumatoid arthritis and systemic lupus erythematosus have a higher incidence of cardiovascular disease and endothelial dysfunction that is not explained by traditional risk factors.50–54 We propose that elevated levels of CRP or circulating immune complexes engage endothelial Fc{gamma}RIIB to attenuate eNOS activity in these patients, thereby adversely affecting endothelial function and possibly contributing to their greater cardiovascular disease risk.

Collectively the present observations reveal a novel series of mechanisms by which CRP is a direct mediator of endothelial dysfunction. Our findings provide a new framework for understanding how CRP, and also circulating immune complexes, may contribute to the pathogenesis of vascular disease. It is anticipated that further research in this realm will lead to new prophylactic and therapeutic strategies to combat the vascular complications of multiple inflammatory and autoimmune disorders


*    Acknowledgments
 
This work was supported by NIH grants HL75473 (to P.W.S.), HL06296 (to G.D.T.), and AG02467 (to D.S.). The project was also supported by American Heart Association Scientist Development Award 0235107N (to C.M.), the Children’s Medical Center Dallas Foundation (to A.K.G.), the Crystal Charity Ball Center for Pediatric Critical Care Research and the Lowe Foundation (to P.W.S.), and the Simmons Family Foundation (to D.R.K.). We are indebted to Miranda King for technical assistance and to Marilyn Dixon for assistance in preparing the manuscript.


*    Footnotes
 
*Both authors contributed equally to this study. Back

Original received May 19, 2005; revision received October 12, 2005; accepted October 20, 2005.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004; 279: 48487–48490.[Abstract/Free Full Text]
  2. Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32: 274–278.[Medline] [Order article via Infotrieve]
  3. Du Clos TW, Mold C. The role of C-reactive protein in the resolution of bacterial infection. Curr Opin Infect Dis. 2001; 14: 289–293.[Medline] [Order article via Infotrieve]
  4. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001; 104: 974–975.[Free Full Text]
  5. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387–1397.[Abstract/Free Full Text]
  6. Jialal I, Devaraj S, Venugopal SK. C-reactive protein:risk marker or mediator in atherothrombosis? Hypertension. 2004; 44: 6–11.[Abstract/Free Full Text]
  7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805–1812.[CrossRef][Medline] [Order article via Infotrieve]
  8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.[Abstract/Free Full Text]
  9. Verma S, Yeh ET. C-reactive protein and atherothrombosis—beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol. 2003; 285: R1253–R1256.[Free Full Text]
  10. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001; 19: 857–861.[CrossRef][Medline] [Order article via Infotrieve]
  11. Van Der Meer IM, de Maat MP, Hak AE, Kiliaan AJ, Del Sol AI, van der Kuip DA, Nijhuis RL, Hofman A, Witteman JC. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002; 33: 2750–2755.[Abstract/Free Full Text]
  12. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000; 102: 1000–1006.[Abstract/Free Full Text]
  13. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003; 108: 512–515.[Abstract/Free Full Text]
  14. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106: 1439–1441.[Abstract/Free Full Text]
  15. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913–919.[Abstract/Free Full Text]
  16. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001; 276: 17625–17628.[Abstract/Free Full Text]
  17. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002; 64: 749–774.[CrossRef][Medline] [Order article via Infotrieve]
  18. Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry. 2002; 41: 15845–15853.[CrossRef][Medline] [Order article via Infotrieve]
  19. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med. 1999; 190: 585–590.[Abstract/Free Full Text]
  20. Crowell RE, Du Clos TW, Montoya G, Heaphy E, Mold C. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J Immunol. 1991; 147: 3445–3451.[Abstract]
  21. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol. 1995; 155: 2185–2193.[Abstract]
  22. Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest. 2000; 105: 369–376.[Medline] [Order article via Infotrieve]
  23. Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J Immunol. 2000; 164: 1514–1520.[Abstract/Free Full Text]
  24. Cassard L, Dragon-Durey MA, Ralli A, Tartour E, Salamero J, Fridman WH, Sautes-Fridman C. Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. Immunol Lett. 2000; 75: 1–8.[CrossRef][Medline] [Order article via Infotrieve]
  25. Pace MC, Chambliss KL, German Z, Yuhanna IS, Mendelsohn ME, Shaul PW. Establishment of an immortalized fetal intrapulmonary artery endothelial cell line. Am J Physiol. 1999; 277: L106–L112.[Medline] [Order article via Infotrieve]
  26. Agrawal A, Simpson MJ, Black S, Carey MP, Samols D. A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol. 2002; 169: 3217–3222.[Abstract/Free Full Text]
  27. Shaul PW, Wells LB, Horning KM. Acute and prolonged hypoxia attenuate endothelial nitric oxide production in rat pulmonary arteries by different mechanisms. J Cardiovasc Pharmacol. 1993; 22: 819–827.[Medline] [Order article via Infotrieve]
  28. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004; 145: 5745–5756.[Abstract/Free Full Text]
  29. Green DD, Yang SI, Mumby MC. Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase. Proc Natl Acad Sci U S A. 1987; 84: 4880–4884.[Abstract/Free Full Text]
  30. Gonzalez E, Nagiel A, Lin AJ, Golan DE, Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J Biol Chem. 2004; 279: 40659–40669.[Abstract/Free Full Text]
  31. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003; 278: 9142–9149.[Abstract/Free Full Text]
  32. Maresh JG, Xu H, Jiang N, Shohet RV. In vivo transcriptional response of cardiac endothelium to lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2004; 24: 1836–1841.[Abstract/Free Full Text]
  33. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A. 1998; 95: 15090–15095.[Abstract/Free Full Text]
  34. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 1996; 379: 346–349.[CrossRef][Medline] [Order article via Infotrieve]
  35. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep. 1996; 23: 253–260.[CrossRef][Medline] [Order article via Infotrieve]
  36. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem. 2001; 276: 16587–16591.[Abstract/Free Full Text]
  37. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001; 19: 275–290.[CrossRef][Medline] [Order article via Infotrieve]
  38. Davignon J, Ganz P Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109 (suppl III): III-27–III-32.[Medline] [Order article via Infotrieve]
  39. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002; 105: 2595–2599.[Abstract/Free Full Text]
  40. Suleiman M, Aronson D, Reisner SA, Kapeliovich MR, Markiewicz W, Levy Y, Hammerman H. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med. 2003; 115: 695–701.[CrossRef][Medline] [Order article via Infotrieve]
  41. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 109: 647–655.[Abstract/Free Full Text]
  42. Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S. Role of C-reactive protein in atherogenesis:can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol. 2005; 25: 1641–1646.[Abstract/Free Full Text]
  43. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005; 102: 8309–8314.[Abstract/Free Full Text]
  44. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol. 1978; 32: 119–124.[Medline] [Order article via Infotrieve]
  45. Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature. 1979; 278: 259–261.[CrossRef][Medline] [Order article via Infotrieve]
  46. Hind CR, Collins PM, Renn D, Cook RB, Caspi D, Baltz ML, Pepys MB. Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. J Exp Med. 1984; 159: 1058–1069.[Abstract/Free Full Text]
  47. Loveless RW, Floyd-O’Sullivan G, Raynes JG, Yuen CT, Feizi T. Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetylgalactosamine and glucuronic acid. EMBO J. 1992; 11: 813–819.[Medline] [Order article via Infotrieve]
  48. Zahedi K. Characterization of the binding of serum amyloid P to laminin. J Biol Chem. 1997; 272: 2143–2148.[Abstract/Free Full Text]
  49. Vielma S, Virella G, Gorod A, Lopes-Virella M. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (FcgammaRII). Clin Immunol. 2002; 104: 265–273.[CrossRef][Medline] [Order article via Infotrieve]
  50. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349: 2407–2415.[Abstract/Free Full Text]
  51. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44: 2737–2745.[CrossRef][Medline] [Order article via Infotrieve]
  52. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349: 2399–2406.[Abstract/Free Full Text]
  53. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107: 1303–1307.[Abstract/Free Full Text]
  54. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004; 63: 31–35.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. J. Ho, C. D. Owens, T. Longo, X. X. Sui, C. Ifantides, and M. S. Conte
C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-{beta}
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1132 - H1140.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. Nagaoka, L. Kuo, Y. Ren, A. Yoshida, and T. W. Hein
C-Reactive Protein Inhibits Endothelium-Dependent Nitric Oxide-Mediated Dilation of Retinal Arterioles via Enhanced Superoxide Production
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2053 - 2060.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai
Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent
Am. J. Pathol., January 1, 2008; 172(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. Teoh, A. Quan, and S. Verma
Does C-reactive protein predict saphenous vein graft patency?
J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 277 - 279.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis
Endothelin-1 Induces Alveolar Epithelial-Mesenchymal Transition through Endothelin Type A Receptor-Mediated Production of TGF-beta1
Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 38 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. Grad, M. Golomb, I. Mor-Yosef, N. Koroukhov, C. Lotan, E. R. Edelman, and H. D. Danenberg
Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H489 - H495.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P. Kumar, Q. Wu, K. L. Chambliss, I. S. Yuhanna, S. M. Mumby, C. Mineo, G. G. Tall, and P. W. Shaul
Direct Interactions with G{alpha}i and G{beta}{gamma} Mediate Nongenomic Signaling by Estrogen Receptor {alpha}
Mol. Endocrinol., June 1, 2007; 21(6): 1370 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. Schwartz, S. Osborne-Lawrence, L. Hahner, L. L. Gibson, A. K. Gormley, W. Vongpatanasin, W. Zhu, R. A. Word, D. Seetharam, S. Black, et al.
C-Reactive Protein Downregulates Endothelial NO Synthase and Attenuates Reendothelialization In Vivo in Mice
Circ. Res., May 25, 2007; 100(10): 1452 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. J. Bisoendial, J. J. P. Kastelein, S. L. M. Peters, J. H. M. Levels, R. Birjmohun, J. I. Rotmans, D. Hartman, J. C. M. Meijers, M. Levi, and E. S. G. Stroes
Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects
J. Lipid Res., April 1, 2007; 48(4): 952 - 960.
[Abstract] [Full Text] [PDF]